Ruben Minski's guest appearances

Ruben Minski

Absolute Return Podcast

The Wall Street Resource

Know Who Drives Return

Tal Keinan

John Collins

Chris Young

Grant Johnson

Caleb Barlow

Chris Urmson

David Sherman

Thomas Smith

Michael Thompson

Tim Hentschel

Scott Wagner

Luvleen Sidhu

Steve Cooper

Amit Kumar

David Norris

OwlTail

Boardroom Alpha's David Drapkin welcomes Union Acquisition II CEO Kyle Bransfield and Procaps CEO Ruben Minski to the podcast. The deal goes to vote on September 22, 2021 and ex-redemption on September 17, so this will be one of shareholders' last opportunities to hear from the team before deciding to redeem or go long alongside Kyle and Ruben. Investors should note that ~$65M was already redeemed from trust at their extension vote in April 2021.Episode DetailsIntro to ProcapsWhy Procaps going public now?Decision to go via SPAC rather than IPO?Why Union Acquisition?SPAC history for UnionRedemptions + Capital StructurePIPE InvestorsProcaps valuationGrowth prospectsWhere are the risks?Will Union be a longterm partner?Procaps transition to a public companyWill Union continue in SPACsParting words Kyle P. Bransfield, CEO of Union AcquisitionKyle P. Bransfield is co-founder of Union Acquisition Group and has served as our Chief Executive Officer and a director since our inception. He has also served as director of Union I since November 2017 (and currently sits on the audit, compensation, and nominating and governance committees) and served as its Chief Executive Officer from December 2017 until it completed its merger with Bioceres in March 2019. Mr. Bransfield is a Partner at Exos Financial, leading the firm’s SPAC strategy. Mr. Bransfield has over 14 years of experience in direct equity and debt private markets principal investing, capital raising, and investment banking. Prior to joining Exos, Mr. Bransfield was a partner at Atlantic-Pacific Capital, leading the firm’s global direct private placement and structured investment activities from 2015 to 2019. Prior to Atlantic-Pacific, Mr. Bransfield was an investment banker in Sagent Advisors’ Private Financing Solutions Group from 2014 to 2015. Prior to Sagent, Mr. Bransfield spent five years from 2009 to 2014 as a Principal and General Partner at CS Capital Partners, a Philadelphia-based multi-family office focused on alternative investments. In his role there, he co-managed a portfolio of direct investments, served as an observer to several boards of directors, and fulfilled operating roles within portfolio companies. In 2006, Mr. Bransfield began his career in the Mergers &amp; Acquisitions Group at Stifel Nicolaus Weisel. Mr. Bransfield received a B.S. in Business Administration from American University.Ruben Minski, Founder, Chief Executive Officer and DirectorRuben Minski, founder, CEO and president of Procaps Group, with extensive experience and recognition in the pharmaceutical industry. Chemical Engineer from Northeastern University in Boston, Massachusetts, he participated in the Owners/President Management program at Harvard University - School of Business, CEOs' II: The Next Step in Strategic Management and in the CEOs' Management Program at Kellogg School of Management at Northwestern University, USA.

Boardroom Alpha's David Drapkin welcomes Union Acquisition II CEO Kyle Bransfield and Procaps CEO Ruben Minski to the podcast. The deal goes to vote on September 22, 2021 and ex-redemption on September 17, so this will be one of shareholders' last opportunities to hear from the team before deciding to redeem or go long alongside Kyle and Ruben. Investors should note that ~$65M was already redeemed from trust at their extension vote in April 2021. Episode Details<ul><li>Intro to Procaps</li><li>Why Procaps going public now?</li><li>Decision to go via SPAC rather than IPO?</li><li>Why Union Acquisition?</li><li>SPAC history for Union</li><li>Redemptions + Capital Structure</li><li>PIPE Investors</li><li>Procaps valuation</li><li>Growth prospects</li><li>Where are the risks?</li><li>Will Union be a longterm partner?</li><li>Procaps transition to a public company</li><li>Will Union continue in SPACs</li><li>Parting words </li></ul> Kyle P. Bransfield, CEO of Union Acquisition Kyle P. Bransfield is co-founder of Union Acquisition Group and has served as our Chief Executive Officer and a director since our inception. He has also served as director of Union I since November 2017 (and currently sits on the audit, compensation, and nominating and governance committees) and served as its Chief Executive Officer from December 2017 until it completed its merger with Bioceres in March 2019. Mr. Bransfield is a Partner at Exos Financial, leading the firm’s SPAC strategy. Mr. Bransfield has over 14 years of experience in direct equity and debt private markets principal investing, capital raising, and investment banking. Prior to joining Exos, Mr. Bransfield was a partner at Atlantic-Pacific Capital, leading the firm’s global direct private placement and structured investment activities from 2015 to 2019. Prior to Atlantic-Pacific, Mr. Bransfield was an investment banker in Sagent Advisors’ Private Financing Solutions Group from 2014 to 2015. Prior to Sagent, Mr. Bransfield spent five years from 2009 to 2014 as a Principal and General Partner at CS Capital Partners, a Philadelphia-based multi-family office focused on alternative investments. In his role there, he co-managed a portfolio of direct investments, served as an observer to several boards of directors, and fulfilled operating roles within portfolio companies. In 2006, Mr. Bransfield began his career in the Mergers &amp; Acquisitions Group at Stifel Nicolaus Weisel. Mr. Bransfield received a B.S. in Business Administration from American University. Ruben Minski, Founder, Chief Executive Officer and Director Ruben Minski, founder, CEO and president of Procaps Group, with extensive experience and recognition in the pharmaceutical industry. Chemical Engineer from Northeastern University in Boston, Massachusetts, he participated in the Owners/President Management program at Harvard University - School of Business, CEOs' II: The Next Step in Strategic Management and in the CEOs' Management Program at Kellogg School of Management at Northwestern University, USA.

Kyle Bransfield and Ruben Minski on the Union Acquisition II / Procaps SPAC Deal

Procaps Group (LATN) is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in Latin America and has more than 5,000 collaborators working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements and high-potency clinical solutions.

Procaps Group (LATN) is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in Latin America and has more than 5,000 collaborators working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements and high-potency clinical solutions.

Procaps Group (LATN) Ruben Minski, CEO